Abstract
Objective: This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients. Methods: One hundred and forty-four patients aged 61-80 years with mild to moderate essential hypertension (DBF ≥95 mmHg and <110 mmHg at the end of a 2-week placebo run-in period) were randomly assigned to once daily (o.d.) treatment with valsartan 160 mg (n = 73) or enalapril 20 mg (n = 71) for 16 weeks. The patients were examined every 4 weeks during the study, with pre-dose BP (standard mercury sphygmomanometer, Korotkoff I and V) and heart rate (pulse palpation) being recorded at each visit. Cognitive function was evaluated at the end of the wash-out period and after 16 weeks of active treatment by means of five tests (verbal fluency, the Boston naming test, word list memory, word list recall and word list recognition). Results: Both valsartan and enalapril had a clear antihypertensive effect, but the former led to a slightly greater reduction in SBP/DBP at 16 weeks (18.6 ± 4.6/ 13.7 ± 4.0 mmHg vs 15.6 ± 5.1/10.9 ± 3.9 mmHg; P<0.01). Enalapril did not induce any significant changes in any of the cognitive function test scores; valsartan significantly increased the word list memory score (+11.8%; P <0.05 vs baseline and P <0.01 vs enalapril) and the word list recall score (+18.7%; P <0.05 vs baseline and P <0.01 vs enalapril), but not those of the other tests. Conclusion: These findings indicate that, in elderly hypertensive patients, 16 weeks of treatment with valsartan 160 mg o.d. is more effective than enalapril 20 mg o.d. in reducing BP, and (unlike enalapril) improves some of the components of cognitive function, particularly episodic memory.
| Original language | English |
|---|---|
| Pages (from-to) | 863-868 |
| Number of pages | 6 |
| Journal | European Journal of Clinical Pharmacology |
| Volume | 59 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Feb 2004 |
Fingerprint
Keywords
- Cognitive functions
- Enalapril
- Valsartan
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. / Fogari, Roberto; Mugellini, Amedeo; Zoppi, Annalisa; Marasi, Gianluigi; Pasotti, Carlo; Poletti, Luigi; Rinaldi, Andrea; Preti, Paola.
In: European Journal of Clinical Pharmacology, Vol. 59, No. 12, 02.2004, p. 863-868.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension
AU - Fogari, Roberto
AU - Mugellini, Amedeo
AU - Zoppi, Annalisa
AU - Marasi, Gianluigi
AU - Pasotti, Carlo
AU - Poletti, Luigi
AU - Rinaldi, Andrea
AU - Preti, Paola
PY - 2004/2
Y1 - 2004/2
N2 - Objective: This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients. Methods: One hundred and forty-four patients aged 61-80 years with mild to moderate essential hypertension (DBF ≥95 mmHg and <110 mmHg at the end of a 2-week placebo run-in period) were randomly assigned to once daily (o.d.) treatment with valsartan 160 mg (n = 73) or enalapril 20 mg (n = 71) for 16 weeks. The patients were examined every 4 weeks during the study, with pre-dose BP (standard mercury sphygmomanometer, Korotkoff I and V) and heart rate (pulse palpation) being recorded at each visit. Cognitive function was evaluated at the end of the wash-out period and after 16 weeks of active treatment by means of five tests (verbal fluency, the Boston naming test, word list memory, word list recall and word list recognition). Results: Both valsartan and enalapril had a clear antihypertensive effect, but the former led to a slightly greater reduction in SBP/DBP at 16 weeks (18.6 ± 4.6/ 13.7 ± 4.0 mmHg vs 15.6 ± 5.1/10.9 ± 3.9 mmHg; P<0.01). Enalapril did not induce any significant changes in any of the cognitive function test scores; valsartan significantly increased the word list memory score (+11.8%; P <0.05 vs baseline and P <0.01 vs enalapril) and the word list recall score (+18.7%; P <0.05 vs baseline and P <0.01 vs enalapril), but not those of the other tests. Conclusion: These findings indicate that, in elderly hypertensive patients, 16 weeks of treatment with valsartan 160 mg o.d. is more effective than enalapril 20 mg o.d. in reducing BP, and (unlike enalapril) improves some of the components of cognitive function, particularly episodic memory.
AB - Objective: This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients. Methods: One hundred and forty-four patients aged 61-80 years with mild to moderate essential hypertension (DBF ≥95 mmHg and <110 mmHg at the end of a 2-week placebo run-in period) were randomly assigned to once daily (o.d.) treatment with valsartan 160 mg (n = 73) or enalapril 20 mg (n = 71) for 16 weeks. The patients were examined every 4 weeks during the study, with pre-dose BP (standard mercury sphygmomanometer, Korotkoff I and V) and heart rate (pulse palpation) being recorded at each visit. Cognitive function was evaluated at the end of the wash-out period and after 16 weeks of active treatment by means of five tests (verbal fluency, the Boston naming test, word list memory, word list recall and word list recognition). Results: Both valsartan and enalapril had a clear antihypertensive effect, but the former led to a slightly greater reduction in SBP/DBP at 16 weeks (18.6 ± 4.6/ 13.7 ± 4.0 mmHg vs 15.6 ± 5.1/10.9 ± 3.9 mmHg; P<0.01). Enalapril did not induce any significant changes in any of the cognitive function test scores; valsartan significantly increased the word list memory score (+11.8%; P <0.05 vs baseline and P <0.01 vs enalapril) and the word list recall score (+18.7%; P <0.05 vs baseline and P <0.01 vs enalapril), but not those of the other tests. Conclusion: These findings indicate that, in elderly hypertensive patients, 16 weeks of treatment with valsartan 160 mg o.d. is more effective than enalapril 20 mg o.d. in reducing BP, and (unlike enalapril) improves some of the components of cognitive function, particularly episodic memory.
KW - Cognitive functions
KW - Enalapril
KW - Valsartan
UR - http://www.scopus.com/inward/record.url?scp=1542616497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542616497&partnerID=8YFLogxK
U2 - 10.1007/s00228-003-0717-9
DO - 10.1007/s00228-003-0717-9
M3 - Article
VL - 59
SP - 863
EP - 868
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
SN - 0031-6970
IS - 12
ER -